RBD1119 / Suzhou Ribo - LARVOL DELTA

Suzhou Ribo Life Science…and Ribocure Pharmaceuticals…announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease (CAD). (Press Release Hub)

New P2 trial • Coronary Artery Disease

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd.

New P1 trial